All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Worldwide, approximately 1,000 children are born daily with sickle cell disease\[[@pone.0223043.ref001]--[@pone.0223043.ref003]\]. The disease is the most common genetic disease in sub-Saharan Africa accounting for over 5% of under-five mortality in Africa \[[@pone.0223043.ref002],[@pone.0223043.ref004],[@pone.0223043.ref005]\]. The clinical manifestation of SCD range from mild to very severe symptoms across the ages. Genotype, the volume of foetal haemoglobin (HbF) and comorbidities have been suggested as factors responsible for degree of severity\[[@pone.0223043.ref006]--[@pone.0223043.ref010]\]. Some of the acute and chronic clinical manifestations include painful crisis, vaso-occlusive episodes, stroke, anaemia, hand-foot syndrome, jaundice, frequent infections, delayed growth, vision problems, aplastic crisis, acute chest syndrome, leg ulcers, priapism, pulmonary hypertension and organ damage \[[@pone.0223043.ref009],[@pone.0223043.ref011]--[@pone.0223043.ref016]\]. Though survival has increased in the last four decades such that people with SCD can now live into the fifth decade of life \[[@pone.0223043.ref017]--[@pone.0223043.ref020]\], the impact on the HRQL of the affected individual is substantial\[[@pone.0223043.ref021]--[@pone.0223043.ref023]\]. Consequently, studies have recognised the importance of HRQL and cost-effectiveness of interventions as outcome measures in addition to survival and morbidity \[[@pone.0223043.ref024]\].

The common and widely accepted means of measuring HRQL is through psychometric, non-preference-based, methods. Such methods do not provide utilities to assess preferences of the patient or to carry out cost-effectiveness analysis of therapy.While non-preference-based methods have been used to investigate HRQL in SCD\[[@pone.0223043.ref023],[@pone.0223043.ref025]--[@pone.0223043.ref028]\], preference-based studies have been lacking. Non-preference-based methods focus on functions in the domains of health assessed, while preference-based or utility measures explore how patients (or the general population) value experiencing a given health state that is defined by functioning and well-being in those domains. The utility approach focuses on the respondents' valuations of their (health) states whereby outcomes are measured in terms of the preferences that individuals express for being in particular states. The measures combine a descriptive component with the respective valuation component, where the valuation part reflects the values that a society attaches to different health states\[[@pone.0223043.ref029]\]. While non-preference-based measures aim to measure health (or change in health) perceived by individuals, the objective of a utility measure is to value health states\[[@pone.0223043.ref029]\].

Quality-of-life measures provide ratings or rankings of health and life\[[@pone.0223043.ref030]\]. Utility measures move the measurement of quality of life from rankings to judgments of the worth or value of life with a given state of health. The utility approach to healthcare is based on modern utility theory--a model of rational decision-making under uncertainty as posited by von Neuman and Morgenstern \[[@pone.0223043.ref031]\]. They argued that utilities are indicators of an individual's preference for particular outcomes or health state under conditions of uncertainty. It has been suggested that the utility approach is a viable alternative for investigators to use in measuring health-related quality of life \[[@pone.0223043.ref032],[@pone.0223043.ref033]\].

Utility measures provide single scores across domains of health that range from 0 to 1, (0 ="dead", and 1 = "perfect health"). A single utility score is important for a variety of reasons one of which is to assess cost effectiveness of interventions with the aim of making informed decisions on the use of healthcare resources \[[@pone.0223043.ref024]\]. In addition, utility can be used to compare different therapies, such as in comparative effectiveness research\[[@pone.0223043.ref034]\]. For example, an intervention that produces a difference in utility of 0.03--0.04 is of clinical importance\[[@pone.0223043.ref035]\] because utilities attach numerical value to the strength of individual, population or society preference for different health outcomes\[[@pone.0223043.ref036]\]. Furthermore, utility can be used to measure overall health impact to aid decision making. Moreover, utility scores can be combined with life-expectancy estimates to obtain the quality-adjusted life years (QALYs) which is useful for economic evaluations of cost and effectiveness. Health economic analysis of new medical interventions require preference-based weighted measures of quality of life utilities to estimate QALYs\[[@pone.0223043.ref037]\]. QALYs are valuable in economic evaluations because they incorporate the gained life years as well as the quality of life years to enhance informed decision making. QALYs are the preferred outcome in cost-effectiveness studies which enables comparisons between treatment alternatives \[[@pone.0223043.ref038]\].

Moreover, utility values are useful in quantifying signs and symptoms related to healthcare, and desirability of a particular disease state according to how a patient perceives his or her life\[[@pone.0223043.ref039],[@pone.0223043.ref040]\]. This is useful in evidence-based medicine where best clinical decision-making is a product of high quality clinical research, clinician's expertise and experience and the patient's values, desires and perspectives\[[@pone.0223043.ref041]\]. Furthermore, the efficacy of a medical intervention in improving patient quality of life can be measured by examining improvement in utility values\[[@pone.0223043.ref042]\].

Utilities are intended for use in any population or disease group \[[@pone.0223043.ref043]\] and thusare relevant in SCD. However, to our knowledge studies on determinants of utilities in SCD have been lacking in existing literature. Anie et al \[[@pone.0223043.ref036]\] examined the relationship between self-reported pain, mood and utility in adults with SCD during and after hospital admission. In contrast, our study examined biological, psychosocial and sociodemographic determinants of utilities in adults with SCD who visited hospital for routine medical appointments. The aims of this study therefore were (1) to describe HRQL using a preference-based approach in SCD patients in Nigeria and (2) to investigate socio-demographic, bio-physiological and psychosocial predictors of utility score in the study population. The results can be used to compare the burden of SCD to other disease conditions as well as form an important parameter in cost utility analyses.

Methods {#sec005}
=======

Sample and design {#sec006}
-----------------

Data for this cross-sectional study were collected at the outpatient units of two sickle cell clinics in Ibadan, the University College Hospital (UCH) and Adeoyo General Hospital. We used a convenience sampling method whereby participants were recruited as they arrived at the clinics. The purpose of the research was explained to them and were told of their rights to participate or to withdraw at anytime during the exercise. They were given informed consent forms to read and sign if they agreed to participate. Respondents were made up of 200 adults diagnosed with SCD, aged 18 years and older (see [Table 1](#pone.0223043.t001){ref-type="table"}).

10.1371/journal.pone.0223043.t001

###### Demographic information of the participants (n = 200).

![](pone.0223043.t001){#pone.0223043.t001g}

  -------------------------------------- --------------- ------------
  Variables                              Frequency       Percentage
  *Gender*                                                
  Male                                   83              41.5
  Female                                 117             58.5
  *Genotype*                                              
  HbSS                                   170             85
  HbSC                                   30              15
  *Marital Status*                                        
  Never Married                          151             75.5
  Married                                41              20.5
  Other (separated, divorced, widowed)   8               4
  *Education*                                             
  Primary                                19              9.5
  Secondary                              97              48.5
  Post-secondary                         84              42
  *Employment status*                                     
  Full employment                        127             63.5
  Part-time employment                   30              15
  Not employed                           43              21.5
  *Income level*                                          
  Below minimum wage                     167             83.5
  ≥ Minimum wage                         33              15.5
  *Living situation*                                      
  Living alone                           18              9
  Living with others                     182             91
  *Have a confidant*                                      
  No                                     29              14.5
  Yes                                    171             85.5
  *Religion*                                              
  Christian                              105             52.5
  Muslim                                 94              47
  Traditional                            1               0.5
  *Co-morbidity*                                          
  No                                     135             67.5
  Yes                                    65              32.5
  **Co-morbid disease**                  **Frequency**   Percent
  Asthma                                 8               4%
  Arthritis                              11              5.50%
  Diabetes                               6               3%
  Epilepsy                               3               1.50%
  Heart disease                          3               1.50%
  High blood pressure                    16              8%
  Leg ulcers                             25              12.50%
  Lung disease                           9               4.50%
  Pneumonia                              13              6.50%
  Priapism                               17              8.50%
  Stroke                                 3               1.50%
  Others                                 5               2.50%
  -------------------------------------- --------------- ------------

Ethical approval {#sec007}
----------------

The Ethics Board of the University of Ibadan/University College Hospital Ethics Committee and the Research Ethics Committee of the University of Sunderland granted approval for this study.

Instruments {#sec008}
-----------

A personal information questionnaire was administered along with other instruments such as the SF-36, GAD-7 and PHQ-9. The personal information questionnaire was designed to elicit information on socio-demographic variables and self-report of hospitalisation, blood transfusion, pain episodes in the last six months and co-morbidities. Self-reports of co-morbidities tend to be accurate, and therefore represent a reliable and valid measure of actual co-morbidity \[[@pone.0223043.ref044]--[@pone.0223043.ref047]\]. Eleven co-morbidities related to SCD identified in literature\[[@pone.0223043.ref048]--[@pone.0223043.ref052]\] were specified in this instrument. They were asthma, arthritis, diabetes, epilepsy, heart disease, high blood pressure, leg ulcers, lung disease, pneumonia, priapism and stroke. Participants were asked to indicate which of these they had or had been informed by their doctors that they had. Participants were also asked to mention any other diseases they had that were not listed. The co-morbidities were scored for individual respondents (1--12) depending on number of comorbidities. This was re-coded as 0, 1--2, and 3 or more to reduce skewness in the distribution.

Assessment of Utility: Utility could be derived through the direct method which consists of eliciting information from individuals through rating scale (RS), standard gamble (SG) or time trade-off (TTO) techniques. The indirect approach uses multi-attribute utility scales. This involves the use of a questionnaire. Individuals complete the questionnaire to describe their health state, these descriptions are converted to index scores using societal valuations. Health state valuations are normally derived from a representative sample of the general population\[[@pone.0223043.ref053]\]

This study employed the indirect method whereby individuals completed questionnaires to describe health scale which are then converted to index scores using social valuations \[[@pone.0223043.ref043]\]. The Short Form (SF-36) version 1 health survey \[[@pone.0223043.ref054]\]is a widely used general HRQL measure which has been validated across a wide variety of age, race, disease populations including SCD with acceptable psychometric properties \[[@pone.0223043.ref025],[@pone.0223043.ref055]--[@pone.0223043.ref059]\]. The SF-36 contains 36 questions aggregated into 8 domains namely physical function, role limitation, social function, bodily pain, mental health and vitality, role physical and general health. These domains are summarised into two health components, the Physical Component scores (PCS) and the Mental Component score (MCS). The utility measure, SF-6D was derived from 11 of the 36 questions of the SF-36 instrument which include six dimensions (physical function, role limitation, social function, bodily pain, mental health and vitality) that defined 18,000 health states \[[@pone.0223043.ref060]\]. The scoring algorithm to derive SF-6D from SF-36\[[@pone.0223043.ref061]--[@pone.0223043.ref063]\]was requested and obtained from Sheffield University (<http://www.sheffield.ac.uk/scharr/sections/heds/mvh/noncommercial>).The algorithm used preference weights obtained from a sample of the UK general population to generate the SF-6D utility score in the UK population. Utility scores ranged from 0.3 to 1.00 where 1.00 represents "full health".\[[@pone.0223043.ref064]\]. The psychometric properties of SF-6D have been investigated and reported to be acceptable\[[@pone.0223043.ref043]\].

Assessment of anxiety: We used the generalised anxiety disorder (GAD-7) instrument to measure anxiety in the population. GAD-7\[[@pone.0223043.ref065]\]is a 7-item scale developed for screening generalised anxiety disorder in line with the *Diagnostic and Statistical Manual of Mental Disorders* Fourth Edition (DSM-IV)\[[@pone.0223043.ref066]\] diagnoses. Respondents were asked to rate their experience in the last two weeks with respect to how they were bothered by symptoms of anxiety. Rating options were 'not at all', 'several days', 'more than half the days', 'nearly every day'. The ratings were allocated scores of 0,1,2,3 respectively. The GAD-7 total score ranges from 0 to 21. Cut points of 5, 10, and 15 were interpreted as representing mild, moderate and severe levels of anxiety. The instrument has good psychometric properties \[[@pone.0223043.ref065]\] and has been used to measure anxiety in SCD populations in Brazil \[[@pone.0223043.ref067]\] and the USA \[[@pone.0223043.ref068]\].

Assessment of depression: The Patient Health Questionnaire (PHQ) was used to assess depression in the population. The PHQ-9\[[@pone.0223043.ref069]\] is a subscale of the PHQ designed to assess depression in patients. The instrument has been established to be reliable and valid instrument for screening depressive disorder according to the DSM-IV diagnoses \[[@pone.0223043.ref069]\]. Patients were asked to rate how often they had been bothered by each of the depressive symptoms in the last two weeks. Experiences were rated from 0, 'not at all' to 3, 'nearly every day'. The total possible score ranges from 0 to 27. Symptoms of depression were assumed to be minimal for score \< 5, mild = 5--9, moderate = 10--14, and severe, ≥15 \[[@pone.0223043.ref070]\]. PHQ-9 has been shown to be equal or superior to other measures of depression \[[@pone.0223043.ref071]--[@pone.0223043.ref073]\]. The psychometric properties of PHQ-9 have been well documented \[[@pone.0223043.ref070]\] and have been used in measuring depression in SCD \[[@pone.0223043.ref067],[@pone.0223043.ref068],[@pone.0223043.ref074],[@pone.0223043.ref075]\]. Items left blank (missing data) were filled with the mean scores of the completed items provided missing items were less than 20%, otherwise the item was treated as completely missing for the individual; this approach was considered to have a lower risk of missing persons with depression, anxiety or somatisation \[[@pone.0223043.ref070]\]. However, no item or respondent in this study had up to 20% missing values.

Assessment of pain and hospital admissions: The measures were made up of events in the life of the participants in the last six months prior to data collection. Participants were asked to indicate the number of times they have been admitted into the hospital in the last 6 months on a scale of 0 (none) to 4 (more than three times). In the same vein, they were asked to state how many times they had had pain episodes in the last 6 months on the same scale.

Reliability: Though the psychometric properties of these instruments have been established in different studies, populations and countries, However, researchers have suggested that investigators should not rely on published reliability estimates because alpha is a property obtained from a specific sample of the population being tested \[[@pone.0223043.ref076],[@pone.0223043.ref077]\]. Reliability was investigated using the Cronbach alpha \[[@pone.0223043.ref078]\].

Statistical analysis {#sec009}
--------------------

Statistical analyses were performed using SPSS version 24 (SPSS, Inc., Chicago). Descriptive statistics were computed for all the variables. Means and standard deviations were obtained for continuous variables, and frequencies and percentages for the categorical variables. Utility scores were presented as mean values, standard deviations (SD) and 95% confidence interval (CI). The Shapiro-Wilk test indicated that the utility score distribution in the population was normal (Shapiro-Wilk = 0.994, p = 0.601). We also report utility score stratified by socio-demographic variables. Student's t-test was used to compare utility between two independent variables and one-way analysis of variance (ANOVA) with post-hoc analysis was used in variables with more than two categories. We examined the collinearity statistics to identify possible presence of multi-collinearity. The Tolerance statistic (range 0.36--0.93) and the variance inflation factor (VIF, range 1.1--4.5) statistic showed that multi-collinearity was not present among the independent variables. Possible associations between utility score and other variables was investigated using bivariate correlation. A hierarchical regression was used to test predictors. The independent variables were selected based on previous studies \[[@pone.0223043.ref027],[@pone.0223043.ref048],[@pone.0223043.ref079]--[@pone.0223043.ref081]\]. The variables were entered in three blocks based on order employed in similar studies \[[@pone.0223043.ref082],[@pone.0223043.ref083]\]. The first block was made up of socio-demographic variables namely age, gender, marital status, education, employment and income. The second block consisted of biological variables such as genotype, number of co-morbidities, frequency of pain episode and hospital admission. The third block included psychosocial variables, namely anxiety and depression. Statistical significance was set at 5%. To measure substantive significance, we calculated and classified effect sizes as small (0.3), medium (0.5) or large (0.8) according to Cohen's recommendation \[[@pone.0223043.ref084]\]. The 95% confidence interval (CI) was also computed for variables of interest.

Results {#sec010}
=======

The mean age of participants was 27.9 years (SD: 6.95) with 58.5% of them female (see [Table 1](#pone.0223043.t001){ref-type="table"}). Single participants or Never married constituted 75.5% of the sample, while 20.5% were married, with 4% either divorced or widowed. Eighty-five percent of the participants had the HbSS genotype while 15% were HbSC. There was no Hb thalassemia in the population. The educational profile showed only 9.5% had below secondary education and 42.2% have tertiary education. Only 36% indicated that they had full time or part time employment and about 93% were either living with relatives or friends. Most of the participants reported that they have confidants (85.5%) and 19% percent have children. About one-third (32.5%) of the participants indicated that they had been diagnosed with co-morbidities. The most prevalent co-morbidity was leg ulcers (12.5%) followed by priapism (8.5%) and high blood pressure (8%). Other identified co-morbidities were mostly pain-related, rheumatism, chest pain and back pain.

Sample characteristics {#sec011}
----------------------

The means, standard deviations and confidence intervals of variables for SF-6D, GAD-7 and PHQ-9 were calculated ([Table 2](#pone.0223043.t002){ref-type="table"}). The mean utility score in the population was 0.65 (SD: 0.12; range: 0.310--0.965). The reliabilities of GAD-7 and PHQ-9 were acceptable, (Cronbach- α, 0.90 and 0.82, respectively). The mean anxiety in the population was minimal (GAD-7 \< 5) while depression was mild (5 \<PHQ-9 \< 10). A frequency analysis showed that 12% had moderate to severe anxiety while 19% had moderate to severe depression.

10.1371/journal.pone.0223043.t002

###### Descriptive analysis.
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  ---------------------------------------------------------------------------------------------
  *Instruments*                Variable         Mean    SD           95% CI       Reliability
  ---------------------------- ---------------- ------- ------------ ------------ -------------
  SF-6D (Derived from SF-36)   Utility          0.65    0.12         0.63--0.67   

  GAD-7                        Anxiety          3.86    3.91         3.32--4.40   0.902

  PHQ-9                        Depression       5.14    4.70         4.49--5.79   0.824

  \                            Pain frequency   2.37    1.19         2.20--2.53   
  Questionnaire                                                                   

  Hospital admission           1.495            1.147   1.34--1.66                
  ---------------------------------------------------------------------------------------------

The utility score was lower for those who had co-morbidities than those who did not (see [Table 3](#pone.0223043.t003){ref-type="table"}); this difference was statistically significant (p = 0.001) with an effect size of 0.63. Female gender also had lower utility score but not statistically significant (p = 0.179). There were more patients with HbSS than HbSC genotypes but the difference in their utility scores was not statistically significant (p = 0.894). Those living alone reported lower utility than those living with others such as relatives or friends and thus probably enjoyed support, however this difference was not statistically significant (p = 0.227).

10.1371/journal.pone.0223043.t003

###### Group differences and effects sizes.
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  --------------------------------------- ------- ---------- -------- ------------- -------- ------------ ------------- -----------------
  **Groups**                              **N**   **Mean**   **SD**   **t-value**   **df**   **95% CI**   **p-value**   **Cohen's (d)**
  **Gender**                                                                                                             
  Male                                    83      0.66       0.11     1.35          198      0.64--0.69   0.179         0.17
  Female                                  117     0.64       0.12                            0.62--0.66                  
  **Living situation**                                                                                                   
  Alone                                   18      0.62       0.08     1.213         198      0.58--0.65   0.227         0.3
  With others                             182     0.65       0.12                            0.64--0.67                  
  **Confidants**                                                                                                         
  Yes                                     171     0.651      0.11     0.137         198      0.60--0.70   0.891         0.02
  No                                      29      0.647      0.13                            0.63--0.67                  
  **Genotype**                                                                                                           
  SS                                      170     0.651      0.12     0.133         198      0.63--0.67   0.894         0.03
  SC                                      30      0.648      0.12                            0.61--0.69                  
  **Co-morbidity**                                                                                                       
  No                                      135     0.67       0.12     4.338\*\*     198      0.65--0.69   \<0.001       0.63
  Yes                                     65      0.6        0.1                             0.58--0.63                  
  **Groups**                              **N**   **Mean**   **SD**   **F-value**   **df**   **95% CI**   **p-value**   **Cohen's (d)**
  **Marital Status**                                                  1.141         197                   0.322         0.12
  Never married                           151     0.66       0.12                            0.64--0.68                  
  Married                                 41      0.63       0.09                            0.61--0.66                  
  Others (divorced, separated, widowed)   8       0.61       0.12                            0.53--0.69                  
  **Education**                                                       2.415         197                   0.092         0.16
  ≤ Primary                               19      0.6        0.12                            0.55--0.65                  
  Secondary                               97      0.65       0.11                            0.63--0.67                  
  Post-secondary                          84      0.66       0.12                            0.64--0.67                  
  **Employment**                                                      0.313         197                   0.732         0.06
  Full-Time                               43      0.66       0.11                            0.63--0.67                  
  Part-time                               30      0.64       0.1                             0.60--0.68                  
  Not employed                            127     0.65       0.12                            0.63--0.70                  
  --------------------------------------- ------- ---------- -------- ------------- -------- ------------ ------------- -----------------

\*\* p\< 0.01

Bivariate relationships {#sec012}
-----------------------

The correlation analysis revealed that utility values decreased with an increase in number of co-morbidities (r = -0.32, p\<0.001), depression (-0.34, p\<0.001), anxiety (r = -0.42, p\<0.001, pain frequency (r = -0.31, p\<0.001) and hospital admission (r = -0.16, p\<0.026) but exhibited a positive relationship with level of education (r = 0.14, p = 0.049). The association with age was positive but not statistically significant (r = 0.14, p = 0.054).

Multivariate analysis {#sec013}
---------------------

All the independent variables explained 30.3% of the variation (see [Table 4](#pone.0223043.t004){ref-type="table"}). The socio-demographic factors alone accounted for 7.5%, the predictors were age, education and employment. This increased to 25.4% when the bio-physiological variables were added. Frequency of pain, number of co-morbidities, age and level of education were associated with utility score. Psychosocial variables accounted for an additional 4.9% where anxiety was negatively associated with health utility. Increase in anxiety, frequency of pain and number of co-morbidities led to a reduced utility value while higher level of education positively predicted utility score.

10.1371/journal.pone.0223043.t004

###### Predictors of health utility score.
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  Variables                  BUnstandardized   SE (B)   B Standardized                                  Statistic (t)                                    p-value   R Sqrd   F-change   Sig. F-change
  -------------------------- ----------------- -------- ----------------------------------------------- ------------------------------------------------ --------- -------- ---------- ---------------
  Block 1                                                                                               2.598[\*\*\*](#t004fn003){ref-type="table-fn"}   0.019     0.075    2.598      0.019
  Constant                   0.596             0.057                                                    10.515                                           0.000                         
  Age                        -0.033            0.015    -0.169[\*](#t004fn001){ref-type="table-fn"}     -2.416                                           0.033                         
  Gender                     -0.021            0.017    -0.091                                          -1.295                                           0.197                         
  Marital-status             0.003             0.017    0.015                                           -0.186                                           0.853                         
  Education                  0.035             0.013    0.193[\*\*](#t004fn003){ref-type="table-fn"}    2.632                                            0.009                         
  Employment                 0.042             0.02     0.294[\*](#t004fn001){ref-type="table-fn"}      2.131                                            0.034                         
  Income                     -0.036            0.022    -0.237                                          -1.671                                           0.096                         
  Block 2                                                                                               6.45                                             0         0.254    11.389     \< 0.001
  Constant                   0.655             0.058                                                    11.383                                           0                             
  Age                        -0.031            0.015    -0.159[\*](#t004fn001){ref-type="table-fn"}     -2.139                                           0.034                         
  Gender                     -0.01             0.015    -0.044                                          -0.683                                           0.496                         
  Marital-status             -0.003            0.015    -0.014                                          -0.179                                           0.858                         
  Education                  0.048             0.012    0.263[\*\*](#t004fn002){ref-type="table-fn"}    3.895                                            0                             
  Employment                 0.022             0.018    0.158                                           1.242                                            0.216                         
  Income                     -0.012            0.02     -0.079                                          -0.606                                           0.545                         
  Genotype                   0.009             0.021    0.029                                           0.441                                            0.66                          
  Hospital_admission         -0.006            0.007    -0.059                                          -0.873                                           0.384                         
  Pain-frequency             -0.027            0.007    -0.280[\*\*](#t004fn002){ref-type="table-fn"}   -4.186                                           0                             
  Num-co-morbidity           -0.05             0.013    -0.272[\*\*](#t004fn002){ref-type="table-fn"}   -3.853                                           0                             
  Block 3                                                                                               6.76                                             0         0.303    9.407      \<0.001
  Constant                   0.707             0.058                                                    12.212                                           0                             
  Age                        -0.023            0.014    -0.118                                          -1.611                                           0.109                         
  Gender                     -0.006            0.015    -0.025                                          -0.397                                           0.692                         
  Marital-status             -0.008            0.015    -0.039                                          -0.52                                            0.603                         
  Education                  0.044             0.012    0.241[\*\*](#t004fn002){ref-type="table-fn"}    3.645                                            0                             
  Employment                 0.027             0.018    0.189                                           1.509                                            0.133                         
  Income                     -0.017            0.02     -0.11                                           -0.849                                           0.397                         
  Genotype                   0.002             0.021    0.007                                           0.108                                            0.914                         
  Hospital_admmission        -0.002            0.007    -0.016                                          -0.24                                            0.811                         
  Pain-frequency             -0.028            0.006    -0.284[\*\*](#t004fn002){ref-type="table-fn"}   -4.368                                           0                             
  Num-co-morbidity Anxiety   -0.029            0.014    -0.156\*                                        -1.997                                           0.047                         
  Depression                 -0.037            0.014    -0.229\*                                        -2.604                                           0.01                          
                             -0.005            0.011    -0.043                                          -0.481                                           0.631                         

\*P\<0.05

\*\* P\<0.01

\*\*\* = F statistic

Discussion {#sec014}
==========

Health utilities are designed to investigate HRQL across domains of health to provide a single score that incorporates how patients' (or the general population) value experiencing a given health state that is defined by level of functioning and well-being in those domains. While the source of the values used to initially develop these measures was the general population, such scores are important to measure the burden of diseases. The mean utility score for SCD patients, in our study, (0.65±0.12) compares with the utility score (0.66± 0.26) reported for people with haemochromatosis \[[@pone.0223043.ref085]\] and (0.66±0.14) reported for people with age-related macular degeneration\[[@pone.0223043.ref086]\] but much lower than the utility score (0.75±0.14) reported in adults with type 1 diabetes \[[@pone.0223043.ref087]\], and that for overweight and obese women with urinary incontinence (0.75±0.10) \[[@pone.0223043.ref088]\], and those with chronic kidney disease (0.67±0.13)\[[@pone.0223043.ref089]\].Anie *et al*, \[[@pone.0223043.ref036]\] reported a utility score of 0.39±0.40 for SCD patients on admission for pain which improved to 0.65±0.29 which is similar to our result. Lower utility values indicate that SCD can substantially diminish the HRQL of the affected individual. However, these comparisons should be interpreted with caution as the studies used different methods to derive their respective utility score. For example, the study on haemochromatosis\[[@pone.0223043.ref085]\] used the Assessment of Quality of life 4D(AQOLD-4D), the study by Anie *et al*\[[@pone.0223043.ref036]\] used the EuroQol EQ-5D.

The lower utility scores in women than men found in this study might not be statistically significant, more information is needed to establish if this difference is of clinical importance. Similar conclusion may be applicable to the difference between those living alone and those living with others as it has been suggested that a difference of 0.03 could be clinically important \[[@pone.0223043.ref090],[@pone.0223043.ref091]\]. The finding of a significant difference between those who had at least one co-morbidity compared to those who had none is worthy of comment. SCD patients are a vulnerable, chronically ill population with a high prevalence of co-morbidities which contributed to reduced quality of life in chronic diseases\[[@pone.0223043.ref092]\].

Age was negatively associated with utility, as expected, because SCD patients are exposed to increased clinical complications as they grow older.This supports findings from a general UK population where utility score was reported to decrease as age increased\[[@pone.0223043.ref093]\]due to age-dependent end-organ dysfunction associated with the disease. Before we entered the psychosocial variables into the regression model, age was a significant predictor of utility score, however, the statistical significance disappeared when anxiety and depression were added into the model. We do not know whether age is a confounder in this study especially because a positive relationship was found between age and anxiety. The negative associations of anxiety and depression with health utility found in this study, support previous studies where these variables were reported to associate negatively with HRQL in SCD\[[@pone.0223043.ref067],[@pone.0223043.ref081],[@pone.0223043.ref094],[@pone.0223043.ref095]\]. The multivariate regression modelling showed that pain frequency, anxiety, number of co-morbidities and education were strong predictors of health utility score. In terms of the direction of effects, these impacts were as expected. For example, anxiety included items that measure mental health while pain has been presented as the hallmark of SCD\[[@pone.0223043.ref036],[@pone.0223043.ref096],[@pone.0223043.ref097]\] and is responsible for emergency visits \[[@pone.0223043.ref096]\]. Therefore, their increase or severity was found to associate with decreased utility score. This is a pointer to the need to approach clinical management of SCD taking a multidisciplinary perspective so as to ensure better quality of life for the patients. For example, in addition to interventions that focus on biological and physiological variables, routine investigation of patients' psychiatric status should be integrated into the disease management protocol.

Clinical implications {#sec015}
---------------------

[Table 4](#pone.0223043.t004){ref-type="table"} shows that the beta coefficients ranged between -0.01 and 0.04 on the 0--1 health utility score. According to Walters and Brazier\[[@pone.0223043.ref090]\], the minimally important difference ranges between 0.01 and 0.05 with a weighted average of 0.03. Khanna\[[@pone.0223043.ref091]\] also reported a minimally important difference of 0.03 in systemic sclerosis. All the predictors had the unstandardized beta coefficients with absolute values equal or greater than 0.03 indicating that beyond statistical significance, they may be of clinical importance in the management of SCD as well as to enhance the utility score measure of health-related quality of life. However, more information is needed to establish this assertion.

Limitations {#sec016}
-----------

Owing to the cross-sectional nature of the design it was not possible to definitively establish a causal relationship. Also, the study relied on self-reported co-morbid conditions, although previous studies have established high agreement between self-reported co-morbidities and medical records abstractions \[[@pone.0223043.ref044]--[@pone.0223043.ref047],[@pone.0223043.ref098]\]. The authors did not examine medical records to validate patients' reports of their hospital admissions and pain episodes which could be understated or overstated due to recall errors. SF-6D has been reported to have a floor effect and different derivations of utility measures have been reported to yield different results \[[@pone.0223043.ref087],[@pone.0223043.ref099]\]. However, SF-6D has been reported to be relatively better in discriminating between health states \[[@pone.0223043.ref087],[@pone.0223043.ref100]\]. Our analysis was based on preference weights derived from the UK population because such weighs do not exist in the local population, We are therefore cautious in our interpretations because the standard of living, access to medical facilities and life expectancy are better in the UK. This work could be replicated using different preference-based measures. Further research could also include a longitudinal study of utility in people with SCD using both direct and derived methods. There is also the need to compare direct and derived methods in SCD as well as a comparison of the performance of the different derivation like SF-6D, EQ-5D, HUI3 and so on.

Conclusion {#sec017}
----------

Health utilities are important values necessary to understand the preferences of an individual for different health outcomes and when combined with survival estimates can be employed in cost utility analysis of medical treatment. Study of health utilities has been lacking in SCD,therefore our findings provide an important contribution to knowledge. This study has shown that utility decreases with age, increasing co-morbidities, painful episodes and anxiety;a multidisciplinary approach is therefore required in the management of the disease. In addition, clinical interventions to ameliorate the painful episodic exacerbations of SCD patients and to manage the disease should also consider the influence of co-morbid conditions. The present study suggests that level of education predicted better utility, although there is need for further studies to establish this relationship as there could be other factors influencing this relationship. It is however recommended that SCD patients, especially in sub-Saharan Africa should be encouraged to enrol in open and distance learning programmes which gives them the opportunity to study at their own pace. As SCD affects schooling, educational policy could be designed to give better opportunities to people with SCD; we believe this could potentially enhance their quality of life.
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